Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (619)	12/13/2001 11:46:44 PM
From: eric ross	Respond to of 656

Hi John.... I am sure that AMGEN has taken into consideration all the assets of IMNX. It is for this reason that 35 or more per share will be the starting bid for IMNX IMHO. Otherwise, most of the major shareholders will oppose the merger. Keep in mind that IMNX was trading over 50 at the time when it has less revenue, less visibility. Now that the picture is quite clear for IMNX, they deserve a good premium. In my opinion, IMNX should not settle for anything less than 40.